Targeted therapy for head and neck cancer: signaling pathways and clinical studies

Q Li, Y Tie, A Alu, X Ma, H Shi - Signal transduction and targeted …, 2023 - nature.com
Head and neck cancer (HNC) is malignant, genetically complex and difficult to treat and is
the sixth most frequent cancer, with tobacco, alcohol and human papillomavirus being major …

[HTML][HTML] Animal models in translational medicine: Validation and prediction

T Denayer, T Stöhr, M Van Roy - New Horizons in Translational Medicine, 2014 - Elsevier
Despite large investments in drug development, the overall success rate of drugs during
clinical development remains low. One prominent explanation is flawed preclinical research …

Patient-derived tumour xenografts as models for oncology drug development

JJ Tentler, AC Tan, CD Weekes, A Jimeno… - Nature reviews Clinical …, 2012 - nature.com
Progress in oncology drug development has been hampered by a lack of preclinical models
that reliably predict clinical activity of novel compounds in cancer patients. In an effort to …

Costs and causes of oncology drug attrition with the example of insulin-like growth factor-1 receptor inhibitors

V Jentzsch, L Osipenko, JW Scannell… - JAMA Network …, 2023 - jamanetwork.com
Importance The development of oncology drugs is expensive and beset by a high attrition
rate. Analysis of the costs and causes of translational failure may help to reduce attrition and …

Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer

P Singh, JM Alex, F Bast - Medical oncology, 2014 - Springer
Insulin and insulin-like growth factor (IGF) signaling system, commonly known for fine-tuning
numerous biological processes, has lately made its mark as a much sought-after therapeutic …

Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts

A Capasso, J Lang, TM Pitts, KR Jordan… - … for immunotherapy of …, 2019 - Springer
Background The success of agents that reverse T-cell inhibitory signals, such as anti-PD-
1/PD-L1 therapies, has reinvigorated cancer immunotherapy research. However, since only …

Regulation of IGF-1 signaling by microRNAs

HJ Jung, Y Suh - Frontiers in genetics, 2015 - frontiersin.org
The insulin-like growth factor 1 (IGF-1) signaling pathway regulates critical biological
processes including development, homeostasis, and aging. Dysregulation of this pathway …

Can we unlock the potential of IGF-1R inhibition in cancer therapy?

H King, T Aleksic, P Haluska, VM Macaulay - Cancer treatment reviews, 2014 - Elsevier
IGF-1R inhibitors arrived in the clinic accompanied by optimism based on preclinical activity
of IGF-1R targeting, and recognition that low IGF bioactivity protects from cancer. This was …

Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes

R Yerushalmi, KA Gelmon, S Leung, D Gao… - Breast cancer research …, 2012 - Springer
Insulin-like growth factor-1 receptor (IGF-1R) is expressed in normal and malignant breast
tissue and has been implicated in cell survival and resistance to cytotoxic therapies. We …

Dual inhibition of MEK and PI3K pathway in KRAS and BRAF mutated colorectal cancers

S Temraz, D Mukherji, A Shamseddine - International journal of molecular …, 2015 - mdpi.com
Colorectal cancer (CRC) is a heterogeneous disease with multiple underlying causative
genetic mutations. Genetic mutations in the phosphatidylinositol-3 kinase (PI3K) and the …